[HTML][HTML] Osteopontin (OPN) as a CSF and blood biomarker for multiple sclerosis: A systematic review and meta-analysis
Identifying a reliable biomarker may accelerate diagnosis of multiple sclerosis (MS) and lead
to early management of the disease. Accumulating evidence suggest that cerebrospinal fluid …
to early management of the disease. Accumulating evidence suggest that cerebrospinal fluid …
[PDF][PDF] Osteopontin (OPN) as a CSF and blood biomarker for multiple sclerosis: A systematic review and meta-analysis
E Agah, A Zardoui, A Saghazadeh, M Ahmadi… - PLoS …, 2018 - pdfs.semanticscholar.org
Identifying a reliable biomarker may accelerate diagnosis of multiple sclerosis (MS) and lead
to early management of the disease. Accumulating evidence suggest that cerebrospinal fluid …
to early management of the disease. Accumulating evidence suggest that cerebrospinal fluid …
Osteopontin (OPN) as a CSF and blood biomarker for multiple sclerosis: A systematic review and meta-analysis
E Agah, A Zardoui, A Saghazadeh, M Ahmadi… - PLOS ONE, 2018 - ideas.repec.org
Identifying a reliable biomarker may accelerate diagnosis of multiple sclerosis (MS) and lead
to early management of the disease. Accumulating evidence suggest that cerebrospinal fluid …
to early management of the disease. Accumulating evidence suggest that cerebrospinal fluid …
Osteopontin (OPN) as a CSF and blood biomarker for multiple sclerosis: A systematic review and meta-analysis
E Agah, A Zardoui, A Saghazadeh, M Ahmadi… - PLoS ONE, 2018 - go.gale.com
Multiple sclerosis is a chronic, progressive, immune-mediated central nervous system (CNS)
disorder characterized by inflammation, demyelination and axonal damage leading to …
disorder characterized by inflammation, demyelination and axonal damage leading to …
[引用][C] Osteopontin (OPN) as a CSF and blood biomarker for multiple sclerosis: A systematic review and meta-analysis
E Agah, A Zardoui, A Saghazadeh, M Ahmadi… - PLoS …, 2018 - ui.adsabs.harvard.edu
Osteopontin (OPN) as a CSF and blood biomarker for multiple sclerosis: A systematic review and
meta-analysis - NASA/ADS Now on home page ads icon ads Enable full ADS view NASA/ADS …
meta-analysis - NASA/ADS Now on home page ads icon ads Enable full ADS view NASA/ADS …
[HTML][HTML] Osteopontin (OPN) as a CSF and blood biomarker for multiple sclerosis: A systematic review and meta-analysis
E Agah, A Zardoui, A Saghazadeh, M Ahmadi… - PLoS ONE, 2018 - ncbi.nlm.nih.gov
Identifying a reliable biomarker may accelerate diagnosis of multiple sclerosis (MS) and lead
to early management of the disease. Accumulating evidence suggest that cerebrospinal fluid …
to early management of the disease. Accumulating evidence suggest that cerebrospinal fluid …
[PDF][PDF] Osteopontin (OPN) as a CSF and blood biomarker for multiple sclerosis: A systematic review and meta-analysis
E Agah, A Zardoui, A Saghazadeh, M Ahmadi… - PLoS ONE, 2018 - researchgate.net
Identifying a reliable biomarker may accelerate diagnosis of multiple sclerosis (MS) and lead
to early management of the disease. Accumulating evidence suggest that cerebrospinal fluid …
to early management of the disease. Accumulating evidence suggest that cerebrospinal fluid …
Osteopontin (OPN) as a CSF and blood biomarker for multiple sclerosis: A systematic review and meta-analysis.
E Agah, A Zardoui, A Saghazadeh, M Ahmadi… - Plos one, 2018 - europepmc.org
Identifying a reliable biomarker may accelerate diagnosis of multiple sclerosis (MS) and lead
to early management of the disease. Accumulating evidence suggest that cerebrospinal fluid …
to early management of the disease. Accumulating evidence suggest that cerebrospinal fluid …
Osteopontin (OPN) as a CSF and blood biomarker for multiple sclerosis: A systematic review and meta-analysis
E Agah, A Zardoui, A Saghazadeh, M Ahmadi… - PLOS …, 2018 - econpapers.repec.org
Identifying a reliable biomarker may accelerate diagnosis of multiple sclerosis (MS) and lead
to early management of the disease. Accumulating evidence suggest that cerebrospinal fluid …
to early management of the disease. Accumulating evidence suggest that cerebrospinal fluid …
Osteopontin (OPN) as a CSF and blood biomarker for multiple sclerosis: A systematic review and meta-analysis.
E Agah, A Zardoui, A Saghazadeh, M Ahmadi… - PLoS …, 2018 - search.ebscohost.com
Identifying a reliable biomarker may accelerate diagnosis of multiple sclerosis (MS) and lead
to early management of the disease. Accumulating evidence suggest that cerebrospinal fluid …
to early management of the disease. Accumulating evidence suggest that cerebrospinal fluid …